{"success":true,"data":{"pressRelease":{"id":"33231","rtpr_id":"nGNX4zqt7R","ticker":"KNE","exchange":"","all_tickers":["KNE"],"title":"Kane Biotech Presents Data To Global Wound Care Community at WCET®–NSWOCC® 2026 Joint Congress","author":"Globe Newswire","published_at":"2026-05-13T11:25:00.102Z","article_body":"WINNIPEG, Manitoba, May 13, 2026 (GLOBE NEWSWIRE) -- Kane Biotech Inc.\n(TSX-V:KNE) (the “Company”, “Kane” or “Kane Biotech”) announced\ntoday its participation in the World Council of Enterostomal Therapists and\nNurses Specialized in Wound, Ostomy and Continence Canada\n(“WCET–NSWOCC”) 2026 Joint Congress, held April 24–28, 2026, in\nVancouver, British Columbia.\n\nThe WCET–NSWOCC Joint Congress brings together global clinical leaders in\nwound, ostomy and continence care. Kane Biotech participated as an exhibitor\nand presenter, focusing on educating clinicians on the clinical benefits of\nrevyve Antimicrobial Wound Gel, part of the revyve product family cleared by\nthe U.S. FDA and authorized for sale in Canada.\n\nFDA cleared and Health Canada approved revyve Antimicrobial Wound Gel and\nrevyve Antimicrobial Wound Gel Spray\n\nAt the Congress, Kane Biotech presented a scientific poster: “Re‑Balancing\nthe Wound Environment Leads to Progressive Wound Healing in High‑Risk\nPatients: A Case Study Using a New Thermo‑Reversible Wound Gel.” The case\nstudy demonstrated how rebalancing the wound environment supported progression\ntoward healing in a complex diabetic foot ulcer, highlighting the potential to\nimprove patient outcomes and quality of life.\n\nThe link to the presentation can be found here\n(https://kanebiotech.com/publications-posters/).\n\nThroughout the Congress, Kane Biotech engaged directly with wound care nurses,\nphysicians, and advanced practitioners from Canada and international markets,\nwith a strong emphasis on clinical education.\n\nDiscussions focused on challenges in chronic wounds, the impact of biofilm on\ndelayed healing, and how antimicrobial approaches like revyve can be\nintegrated into standard care. The Company observed strong interest from\nclinicians seeking evidence-based solutions to improve healing outcomes.\n\n“The WCET–NSWOCC Congress was a great opportunity to connect directly with\nclinicians,” said Patti Burke-Martin, Vice President of Business\nDevelopment, Canada. “The discussions reinforced the importance of education\nin helping clinicians improve patient outcomes, while also supporting our\ncommercialization efforts.”\n\nParticipation in WCET–NSWOCC 2026 as an important part of Kane’s strategy\nto educate the global wound care community and advance evidence-based\napproaches to improving patient quality of life.\n\nAbout Kane Biotech Inc. (TSX-V:KNE)\n\nKane Biotech is commercializing and developing novel wound care treatments\nthat disrupt biofilms and transform healing outcomes. Biofilms are one of the\nmain contributors to antibiotic resistance in wounds, resulting in serious\nclinical outcomes and significant cost. revyve addresses both biofilms and\nwound bacteria. revyve Antimicrobial Wound Gel, revyve Antimicrobial Wound Gel\nSpray and revyve Antimicrobial Skin and Wound Cleanser are all U.S. FDA 510(k)\ncleared. revyve Antimicrobial Wound Gel and revyve Antimicrobial Wound Gel\nSpray are also Health Canada approved. To learn more, visit revyvegel.com\n(http://revyvegel.com) or revyvegel.ca (http://revyvegel.ca).\n\nJoin Kane’s Distribution List & Social Media:\n\nTo stay informed on the latest developments, sign up for the Company’s email\ndistribution list here (https://ir.kanebiotech.com/email-alerts).\n\nFollow Kane\n\nWebsite: kanebiotech.com (https://kanebiotech.com/)\n\nLinkedIn: https://www.linkedin.com/company/kanebiotech/\n\nPresentation: Disrupting Biofilms to Save Limbs and Transform Wound Care\n(https://d1io3yog0oux5.cloudfront.net/_e2e6a0e0721853d3ba219356592debae/kanebiotech/db/447/3517/pdf/Kane+Investor+deck+Feb+2026.pdf)\n\n\n\n For more information:                               \n                                                     \n Dr. Robert Huizinga        Ray Dupuis               \n Interim CEO                Chief Financial Officer  \n Kane Biotech Inc.          Kane Biotech Inc.        \n rhuizinga@kanebiotech.com  rdupuis@kanebiotech.com  \n (780) 970-1100             (204) 298-2200           \n                                                     \n\nNeither the TSX Venture Exchange nor its Regulation Services Provider (as that\nterm is defined in policies of the TSX Venture Exchange) accepts\nresponsibility for the adequacy or accuracy of this release.\n\nCaution Regarding Forward-Looking Information\n\nThis press release contains certain statements regarding Kane Biotech Inc.\nthat constitute forward-looking information under applicable\nsecurities law. These statements reflect management’s current beliefs and\nare based on information currently available to management. Certain material\nfactors or assumptions are applied in making forward-looking statements, and\nactual results may differ materially from those expressed or implied in such\nstatements. These risks and uncertainties include, but are not limited to,\nrisks relating to the Company’s: (a) financial condition, including lack of\nsignificant revenues to date and reliance on equity and other financing; (b)\nbusiness, including its early stage of development, government regulation,\nmarket acceptance for its products, rapid technological change and dependence\non key personnel; (c) intellectual property including the ability of the\nCompany to protect its intellectual property and dependence on its strategic\npartners; and (d) capital structure, including its lack of dividends on its\ncommon shares, volatility of the market price of its common shares and public\ncompany costs. Further information about these and other risks and\nuncertainties can be found in the disclosure documents filed by the Company\nwith applicable securities regulatory authorities, available\nat www.sedarplus.ca. The Company cautions that the foregoing list of factors\nthat may affect future results is not exhaustive.\n\nA photo accompanying this announcement is available at\nhttps://www.globenewswire.com/NewsRoom/AttachmentNg/151431c7-16a7-45ce-b235-2e7b037c555a\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/a2ad1d52-1d5a-425c-93de-45cc52c3784b)\nFDA cleared and Health Canada approved revyve Antimicrobial Wound Gel and\nrevyve Antimicrobial Wound Gel Spray \n(https://www.globenewswire.com/NewsRoom/AttachmentNg/151431c7-16a7-45ce-b235-2e7b037c555a/en)\nFDA cleared and Health Canada approved revyve Antimicrobial Wound Gel and\nrevyve Antimicrobial Wound Gel Spray\n\n\nGlobeNewswire, Inc. 2026","article_body_html":"","raw_payload":{"data":{"id":"nGNX4zqt7R","title":"Kane Biotech Presents Data To Global Wound Care Community at WCET®–NSWOCC® 2026 Joint Congress","author":"Globe Newswire","ticker":"KNE","created":"2026-05-13T11:25:00.102Z","tickers":["KNE"],"exchange":"","article_body":"WINNIPEG, Manitoba, May 13, 2026 (GLOBE NEWSWIRE) -- Kane Biotech Inc.\n(TSX-V:KNE) (the “Company”, “Kane” or “Kane Biotech”) announced\ntoday its participation in the World Council of Enterostomal Therapists and\nNurses Specialized in Wound, Ostomy and Continence Canada\n(“WCET–NSWOCC”) 2026 Joint Congress, held April 24–28, 2026, in\nVancouver, British Columbia.\n\nThe WCET–NSWOCC Joint Congress brings together global clinical leaders in\nwound, ostomy and continence care. Kane Biotech participated as an exhibitor\nand presenter, focusing on educating clinicians on the clinical benefits of\nrevyve Antimicrobial Wound Gel, part of the revyve product family cleared by\nthe U.S. FDA and authorized for sale in Canada.\n\nFDA cleared and Health Canada approved revyve Antimicrobial Wound Gel and\nrevyve Antimicrobial Wound Gel Spray\n\nAt the Congress, Kane Biotech presented a scientific poster: “Re‑Balancing\nthe Wound Environment Leads to Progressive Wound Healing in High‑Risk\nPatients: A Case Study Using a New Thermo‑Reversible Wound Gel.” The case\nstudy demonstrated how rebalancing the wound environment supported progression\ntoward healing in a complex diabetic foot ulcer, highlighting the potential to\nimprove patient outcomes and quality of life.\n\nThe link to the presentation can be found here\n(https://kanebiotech.com/publications-posters/).\n\nThroughout the Congress, Kane Biotech engaged directly with wound care nurses,\nphysicians, and advanced practitioners from Canada and international markets,\nwith a strong emphasis on clinical education.\n\nDiscussions focused on challenges in chronic wounds, the impact of biofilm on\ndelayed healing, and how antimicrobial approaches like revyve can be\nintegrated into standard care. The Company observed strong interest from\nclinicians seeking evidence-based solutions to improve healing outcomes.\n\n“The WCET–NSWOCC Congress was a great opportunity to connect directly with\nclinicians,” said Patti Burke-Martin, Vice President of Business\nDevelopment, Canada. “The discussions reinforced the importance of education\nin helping clinicians improve patient outcomes, while also supporting our\ncommercialization efforts.”\n\nParticipation in WCET–NSWOCC 2026 as an important part of Kane’s strategy\nto educate the global wound care community and advance evidence-based\napproaches to improving patient quality of life.\n\nAbout Kane Biotech Inc. (TSX-V:KNE)\n\nKane Biotech is commercializing and developing novel wound care treatments\nthat disrupt biofilms and transform healing outcomes. Biofilms are one of the\nmain contributors to antibiotic resistance in wounds, resulting in serious\nclinical outcomes and significant cost. revyve addresses both biofilms and\nwound bacteria. revyve Antimicrobial Wound Gel, revyve Antimicrobial Wound Gel\nSpray and revyve Antimicrobial Skin and Wound Cleanser are all U.S. FDA 510(k)\ncleared. revyve Antimicrobial Wound Gel and revyve Antimicrobial Wound Gel\nSpray are also Health Canada approved. To learn more, visit revyvegel.com\n(http://revyvegel.com) or revyvegel.ca (http://revyvegel.ca).\n\nJoin Kane’s Distribution List & Social Media:\n\nTo stay informed on the latest developments, sign up for the Company’s email\ndistribution list here (https://ir.kanebiotech.com/email-alerts).\n\nFollow Kane\n\nWebsite: kanebiotech.com (https://kanebiotech.com/)\n\nLinkedIn: https://www.linkedin.com/company/kanebiotech/\n\nPresentation: Disrupting Biofilms to Save Limbs and Transform Wound Care\n(https://d1io3yog0oux5.cloudfront.net/_e2e6a0e0721853d3ba219356592debae/kanebiotech/db/447/3517/pdf/Kane+Investor+deck+Feb+2026.pdf)\n\n\n\n For more information:                               \n                                                     \n Dr. Robert Huizinga        Ray Dupuis               \n Interim CEO                Chief Financial Officer  \n Kane Biotech Inc.          Kane Biotech Inc.        \n rhuizinga@kanebiotech.com  rdupuis@kanebiotech.com  \n (780) 970-1100             (204) 298-2200           \n                                                     \n\nNeither the TSX Venture Exchange nor its Regulation Services Provider (as that\nterm is defined in policies of the TSX Venture Exchange) accepts\nresponsibility for the adequacy or accuracy of this release.\n\nCaution Regarding Forward-Looking Information\n\nThis press release contains certain statements regarding Kane Biotech Inc.\nthat constitute forward-looking information under applicable\nsecurities law. These statements reflect management’s current beliefs and\nare based on information currently available to management. Certain material\nfactors or assumptions are applied in making forward-looking statements, and\nactual results may differ materially from those expressed or implied in such\nstatements. These risks and uncertainties include, but are not limited to,\nrisks relating to the Company’s: (a) financial condition, including lack of\nsignificant revenues to date and reliance on equity and other financing; (b)\nbusiness, including its early stage of development, government regulation,\nmarket acceptance for its products, rapid technological change and dependence\non key personnel; (c) intellectual property including the ability of the\nCompany to protect its intellectual property and dependence on its strategic\npartners; and (d) capital structure, including its lack of dividends on its\ncommon shares, volatility of the market price of its common shares and public\ncompany costs. Further information about these and other risks and\nuncertainties can be found in the disclosure documents filed by the Company\nwith applicable securities regulatory authorities, available\nat www.sedarplus.ca. The Company cautions that the foregoing list of factors\nthat may affect future results is not exhaustive.\n\nA photo accompanying this announcement is available at\nhttps://www.globenewswire.com/NewsRoom/AttachmentNg/151431c7-16a7-45ce-b235-2e7b037c555a\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/a2ad1d52-1d5a-425c-93de-45cc52c3784b)\nFDA cleared and Health Canada approved revyve Antimicrobial Wound Gel and\nrevyve Antimicrobial Wound Gel Spray \n(https://www.globenewswire.com/NewsRoom/AttachmentNg/151431c7-16a7-45ce-b235-2e7b037c555a/en)\nFDA cleared and Health Canada approved revyve Antimicrobial Wound Gel and\nrevyve Antimicrobial Wound Gel Spray\n\n\nGlobeNewswire, Inc. 2026"},"type":"article","timestamp":"2026-05-13T11:25:00.157590098Z","server_sent_at_ms":1778671500157},"received_at":"2026-05-13T11:25:00.289Z","source_url":null},"analysis":{"id":"23787","press_release_id":"33231","analysis_json":{"industry":{"label":"Biotechnology","sector":"Health Care"},"redFlags":[],"eventType":"operations_update","narrative":"Kane Biotech presented data and engaged with clinicians at the WCET–NSWOCC 2026 Joint Congress, held in Vancouver, British Columbia from April 24–28, 2026.\n\nThe company showcased its revyve product family, which is FDA 510(k) cleared and Health Canada approved, focusing on the clinical benefits of revyve Antimicrobial Wound Gel.\n\nA scientific poster titled 'Re-Balancing the Wound Environment Leads to Progressive Wound Healing in High-Risk Patients' highlighted the potential of revyve to improve patient outcomes in complex diabetic foot ulcers.\n\nKane Biotech emphasized the importance of clinical education and observed strong interest from clinicians seeking evidence-based solutions to improve healing outcomes.","sentiment":"neutral","agentHooks":{"shouldPost":false,"suggestedAngle":"Kane Biotech presents data on revyve at major wound care conference."},"keyFigures":{"customDimensions":{"conference_date":"April 24–28, 2026","conference_location":"Vancouver, British Columbia"}},"quotedText":"The WCET–NSWOCC Congress was a great opportunity to connect directly with clinicians","namedEntities":{"people":[{"name":"Patti Burke-Martin","role":"Vice President of Business Development, Canada"},{"name":"Dr. Robert Huizinga","role":"Interim CEO"},{"name":"Ray Dupuis","role":"Chief Financial Officer"}],"products":["revyve Antimicrobial Wound Gel","revyve Antimicrobial Wound Gel Spray","revyve Antimicrobial Skin and Wound Cleanser"],"companies":[{"name":"Kane Biotech Inc.","ticker":"KNE"},{"name":"World Council of Enterostomal Therapists and Nurses Specialized in Wound, Ostomy and Continence Canada","relationship":"conference organizer"}],"dollarAmounts":[]},"materialImpact":{"score":2,"reasoning":"The company presented data and engaged with clinicians at a major industry conference, which is positive for awareness and education but does not directly impact financials or regulatory status."},"tickerRelevance":{"others":[],"primary":"KNE"},"globalImportance":25,"audienceRelevance":35,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"small-cap","eventGravity":"industry conference participation","issuerAuthored":true}},"event_type":"operations_update","event_type_secondary":null,"sentiment":"neutral","material_impact_score":2,"narrative":"Kane Biotech presented data and engaged with clinicians at the WCET–NSWOCC 2026 Joint Congress, held in Vancouver, British Columbia from April 24–28, 2026.\n\nThe company showcased its revyve product family, which is FDA 510(k) cleared and Health Canada approved, focusing on the clinical benefits of revyve Antimicrobial Wound Gel.\n\nA scientific poster titled 'Re-Balancing the Wound Environment Leads to Progressive Wound Healing in High-Risk Patients' highlighted the potential of revyve to improve patient outcomes in complex diabetic foot ulcers.\n\nKane Biotech emphasized the importance of clinical education and observed strong interest from clinicians seeking evidence-based solutions to improve healing outcomes.","key_figures":{"customDimensions":{"conference_date":"April 24–28, 2026","conference_location":"Vancouver, British Columbia"}},"named_entities":{"people":[{"name":"Patti Burke-Martin","role":"Vice President of Business Development, Canada"},{"name":"Dr. Robert Huizinga","role":"Interim CEO"},{"name":"Ray Dupuis","role":"Chief Financial Officer"}],"products":["revyve Antimicrobial Wound Gel","revyve Antimicrobial Wound Gel Spray","revyve Antimicrobial Skin and Wound Cleanser"],"companies":[{"name":"Kane Biotech Inc.","ticker":"KNE"},{"name":"World Council of Enterostomal Therapists and Nurses Specialized in Wound, Ostomy and Continence Canada","relationship":"conference organizer"}],"dollarAmounts":[]},"model_name":"Qwen/Qwen2.5-72B-Instruct-AWQ","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-05-13T11:25:20.130Z","global_importance":25,"audience_relevance":35,"importance_components":{"tickerTier":"small-cap","eventGravity":"industry conference participation","issuerAuthored":true}},"durationMs":19791,"modelName":"george-droid-qwen-72b"}}